21:41 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Engage, Integra raise venture financings

Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million on Sept. 27 in a series A round led...
00:04 , Sep 28, 2017 |  BC Extra  |  Financial News

Venture roundup: Engage, Integra

On Wednesday, epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million in a series A round led...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Staccato alprazolam: Interim Phase IIa data

Interim data from 3 epileptics with acute repetitive seizures in a double-blind, crossover, U.S. Phase IIa trial showed that single doses of 0.5, 1 and 2 mg inhaled AZ-002 led to dose-related reductions in mean...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Alexza drug delivery, neurology news

Alexza retained Guggenheim Securities to explore strategic options, including the sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions. Alexza’s Adasuve loxapine -- loxapine delivered by...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

Staccato alprazolam: Phase IIa started

Alexza began a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate a single dose of 0.5, 1 and 2 mg inhaled Staccato in about 6 patients. Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif.   Product:...
07:00 , May 6, 2013 |  BioCentury  |  Regulation

The patient voice

While the first meeting under FDA's Patient-Focused Drug Development initiative focused only on one disease - chronic fatigue syndrome - it did make clear the challenges the agency faces in making use of anecdotal information...
08:00 , Feb 15, 2010 |  BioCentury  |  Finance

Faintly rewarded

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) did a round trip following Wednesday's announcement granting Biovail Corp. (TSX:BVF; NYSE:BVF) exclusive rights in the U.S. and Canada to develop and commercialize Staccato loxapine (AZ-004). At its low point during...
08:00 , Jan 28, 2010 |  BC Innovations  |  Targets & Mechanisms

Putting anxiety to rest

Orexin's role in narcolepsy and appetite has made receptors for the neuropeptide attractive targets for sleep and diet disorders. Now, a report from Indiana University researchers has shown that one of the brain hormone's two...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Company News

Alexza, Symphony Allegro deal

Alexza exercised its option to acquire Symphony Allegro in a stock deal. Alexza gained the option in 2006 when it out-licensed neurology compounds to Symphony Allegro, which was formed by Symphony Capital with an investment...
07:00 , Jun 22, 2009 |  BioCentury  |  Finance

Ebb & Flow

If Symphony Capital had been able to make good on the original buyback terms of its 2006 deal with Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Symphony would have doubled its money. But times being what they are,...